cross-hla targeting of intracellular oncoproteins with peptide-centric cars cross - at-what-age-should-i-start-using-peptides intracellular Cross-HLA Targeting of Intracellular Oncoproteins with Peptide-Centric CARs: A Novel Immunotherapeutic Approach

creme-peptide-et-ceramide The dominant search intent revolves around understanding and detailing the scientific concept of "cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs." This involves exploring a specific type of immunotherapy that utilizes peptide-centric chimeric antigen receptors (CARs) to target intracellular oncoproteins, overcoming limitations imposed by HLA presentation.

Tier 1 Entities & Phrases:

* Core Topic: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs

* Key Technology: Peptide-centric CARs (PC-CARs)

* Target: Intracellular oncoproteins

* Mechanism: Cross-HLA targeting, peptide presentation, HLA allotypes

Tier 2 Entities & Phrases:

* Neuroblastoma

* PHOX2B (a specific oncoprotein)

* Counter-panning strategy

* Unmutated peptides

* Immunotherapy

* T cell therapy

Tier 3 Entities & Phrases:

* Specific publication dates, journal names, author names (unless they are crucial for context, which they are not here as the concept is the focus).作者：M Yarmarkovich·2023—This retracts the article "RETRACTED ARTICLE:Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs" in volume 599 on page ...

* Retraction notices (these indicate the topic is still under scientific scrutiny and may not be the primary focus for a general explanation).

* Redundant or overly specific phrasing that doesn't add conceptual value.

---

The field of cancer immunotherapy has seen significant advancements, with chimeric antigen receptor (CAR) T-cell therapy emerging as a powerful tool. However, a major limitation has been the inability to effectively target intracellular oncoproteins, which constitute the majority of cancer-driving proteins. A groundbreaking approach, termed cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs, has been developed to overcome this challengeA roadmap for driving CAR T cells toward the oncogenic .... This innovative strategy utilizes peptide-centric CARs (PC-CARs) to recognize intracellular oncoproteins presented on the cell surface via Human Leukocyte Antigen (HLA) molecules, thereby expanding the scope of immunotherapeutic targets.

The Challenge of Intracellular Oncoproteins

Oncogenic drivers, many of which are intracellular proteins, are responsible for cancer development and progression. Traditional immunotherapies, including CAR T-cell therapy, primarily target surface antigens.New Class of "Peptide-Centric" CAR-T Cells Eradicates ... This leaves a vast pool of intracellular oncoproteins inaccessible to current treatment modalities.... CARS are able to recognize the PHOX2B peptide on different HLA types. Most ...Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. To address this, researchers have focused on identifying ways to present fragments of these intracellular proteins, known as peptides, on the cell surface. These peptides are then loaded onto HLA molecules, which act as presenters to T-cells. However, the diversity of HLA types across individuals (HLA polymorphism) presents a significant hurdle, as a CAR designed to recognize a specific peptide-HLA complex might only be effective in a subset of patients.

Peptide-Centric CARs: A Solution for Broad Targeting

The development of peptide-centric CARs represents a significant leap forward. Unlike conventional CARs that recognize intact surface proteins, PC-CARs are engineered to specifically bind to peptide-HLA complexes.作者：M Yarmarkovich·2023—Retraction Note:Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Mark Yarmarkovich,; Quinlen F. Marshall ... This "peptide-centric" design allows for the recognition of intracellular oncoproteins that are processed into peptides and presented by HLA molecules.

A key innovation in this approach is the development of strategies that enable cross-HLA targeting. This means that a single PC-CAR design can potentially recognize the same target peptide presented by multiple different HLA allotypes. This ability is crucial for developing broadly applicable immunotherapies that can benefit a larger patient population, irrespective of their specific HLA genetic makeup... CARS are able to recognize the PHOX2B peptide on different HLA types. Most ...Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs..

Mechanism of Action and Potential Applications

PC-CARs function by binding to the peptide-HLA complex presented on cancer cells. This binding then triggers a T-cell response, leading to the targeted killing of cancer cells2021年11月12日—本文研究数据表明，以肽为中心的CAR有可能极大地扩展免疫治疗靶点库，包括非免疫性的细胞内肿瘤蛋白，并通过打破传统的HLA限制，扩大受益于这种治疗的患者群体 .... The specificity of the CAR is directed towards peptides derived from oncoproteins, ensuring that the immune system primarily attacks malignant cells while sparing healthy tissues.

Early research has demonstrated the potential of this approach in preclinical models.New Class of CAR-T cells eradicates neuroblastoma in mice For instance, PC-CARs targeting the neuroblastoma oncoprotein PHOX2B have shown promising results, completely and selectively eliminating neuroblastoma tumors in mice. This success highlights the therapeutic potential of PC-CARs for various cancers driven by intracellular oncoproteins.

Overcoming HLA Diversity

The inherent diversity of HLA molecules is a major challenge in developing universal cancer therapies. Each individual possesses a unique set of HLA alleles, influencing which peptides are presented on their cell surfaces. Traditional CARs that rely on recognizing specific peptide-HLA complexes would therefore need to be tailored to individual patient HLA types, a complex and costly endeavor(PDF) Cross-HLA targeting of intracellular oncoproteins ....

The cross-HLA targeting capability of peptide-centric CARs aims to circumvent this limitation. By designing CARs that can recognize a specific peptide presented by a wide range of common HLA allotypes, it becomes possible to create off-the-shelf therapies that are effective across diverse patient populations. This is achieved through strategies like counter-panning with predicted potentially cross-reactive peptides, allowing for the engineering of CARs with optimal recognition across different HLAs.

Future Directions and Implications

The development of peptide-centric CARs for cross-HLA targeting of intracellular oncoproteins opens up new avenues for cancer immunotherapy.以肽为中心的CAR实现细胞内肿瘤蛋白的交叉HLA靶向 - 新闻 This approach has the potential to significantly expand the repertoire of treatable cancers by making previously inaccessible intracellular targets available for immune attack. Further research and clinical trials are necessary to fully realize the promise of this technology, including optimizing CAR design, identifying novel oncoprotein targets, and ensuring safety and efficacy in human patients. The ability to broadly target intracellular oncoproteins represents a significant advancement in the ongoing fight against cancer.RETRACTED ARTICLE: Cross-HLA targeting of ...